Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Unidym Inc. Spins off Ensysce Biosciences Inc. to Pursue Medical Therapeutic Applications of Carbon Nanotubes

Abstract:
Unidym, Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today the formation of a spin-off company, Ensysce Biosciences Inc., that will focus on research into the medical therapeutic applications of carbon nanotubes. Unidym has licensed its extensive nanotechnology patent portfolio to Ensysce for this field of use and in return holds a significant equity position in Ensysce. The inception of Ensysce stems from the final research interests of the late Dr. Richard Smalley, the 1996 Nobel Laureate for Chemistry from Rice University, who was among the pioneers in considering the potential therapeutic applications for carbon nanotubes. Unidym acquired rights to Dr. Smalley's work in carbon nanotechnology through a corporate merger in April of last year.

Unidym Inc. Spins off Ensysce Biosciences Inc. to Pursue Medical Therapeutic Applications of Carbon Nanotubes

Menlo Park, CA | Posted on March 18th, 2008

"Unidym's carbon nanotubes have been widely used in a variety of very promising medical therapeutic research," noted Art Swift, Unidym's president and CEO. "Given the broad applicability of our IP portfolio, it was a natural move to create this spin-off company to, over time, return previously untapped value to Unidym's shareholders by focusing on the application of our intellectual property in medical therapeutics for the systemic treatment of disease, an area that is outside Unidym's core business focus on electronics applications for carbon nanotechnology."

Ensysce will immediately begin working with several of the world's leading chemists and clinicians in the field developing carbon nanotube based therapeutics. One of its first moves is to fund the existing studies using carbon nanotubes for delivery of short interfering RNA (siRNA) using animal models, led by Dr. Bruce Weisman at Rice University and Dr. Garth Powis at the University of Texas M. D. Anderson Cancer Center.

"We have a strong group between our two organizations working in the area of siRNA and are looking forward to working closely with Ensysce," said Dr. Bruce Weisman of Rice University. "In addition to funding our research, Ensysce will provide a clear path to market for our work."

In parallel, Ensysce will immediately fund the research at Stanford University being led by Dr. Hongjie Dai and focused on the delivery of chemotherapy drugs such as taxol and doxorubicin using carbon nanotubes.

"We have made significant progress in delivering chemotherapy drugs into tumor cells and have reached the point where we hope to work with a commercial entity to take our work to the next level," said Dr. Hongjie Dai of Stanford University. "Ensysce's participation in our work could help us progress to animal trials for a solution to substantially increase the efficacy of chemotherapy drugs, while reducing toxicity outside of tumor cells."

Ensysce is also looking at novel ways of using carbon nanotubes to directly treat tumor cells. As a part that research funding program, Ensysce will also fund a team led by Dr. Lon Wilson of Rice University and Dr. Steven Curley of the M. D. Anderson Cancer Center. This team is preparing to move into human trials a cancer therapy that uses carbon nanotubes exposed during treatment to RF radiation.

Terms of the licensing arrangement between Unidym and Ensysce were not announced, but include up-front licensing fees, ongoing royalties, and a significant equity position for Unidym in Ensysce Biosciences. In addition, Unidym will provide contract services to Ensysce, including supplies of research grade nanotubes, back-office and accounting support. Initial operating costs of the new venture, including the funded research at Rice, M.D. Anderson and Stanford, are funded by an angel investor interested in the therapeutic applications of carbon nanotubes. Ensysce expects to put an experienced biotech management team in place after it generates initial animal data from its funded research.

####

About Unidym, Inc.
Unidym (www.unidym.com) is a leader in the manufacture and application of carbon nanotubes (CNTs), a novel material with extraordinary electrical, thermal, and mechanical properties. Unidym provides bulk materials, CNT-enabled products, and intellectual property to a wide range of customers and business partners. As a result of its recent merger with CNI, Unidym possesses a foundational patent portfolio that covers nearly every aspect of CNT manufacturing and processing as well as multiple product applications.

Unidym is focused on the electronics industry where its initial products include transparent electrodes for touch screens, flat panel displays, solar cells, and solid state lighting; electrodes for fuel cells; and thin film transistors for printable electronics. Unidym is also pursuing an aggressive, cross-industry partnership strategy to capture value from the wide ranging uses of CNTs. Unidymís licensing program, technical expertise and manufacturing facilities can enable partners to rapidly develop CNT solutions for their specific applications.

Unidym is a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR).

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. One can identify these forward-looking statements by the use of the words "expect," "anticipate," "plan," "may," "will," "estimate" and other similar expressions. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Arrowhead Research Corporation's latest Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K, Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking st

For more information, please click here

Contacts:
Unidym, Inc.
Robert Bismuth, 650-462-1935

or
Arrowhead Research
Virginia Dadey, 212-541-3707

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

'Lasers rewired': Scientists find a new way to make nanowire lasers: Berkeley Lab, UC Berkeley scientists adapt next-gen solar cell materials for a different purpose February 12th, 2016

Breaking cell barriers with retractable protein nanoneedles: Adapting a bacterial structure, Wyss Institute researchers develop protein actuators that can mechanically puncture cells February 12th, 2016

Replacement of Toxic Antibacterial Agents Possible by Biocompatible Polymeric Nanocomposites February 12th, 2016

Properties of Polymeric Nanofibers Optimized to Treat Damaged Body Tissues February 12th, 2016

Nanotubes/Buckyballs/Fullerenes

Superconductivity: Footballs with no resistance - Indications of light-induced lossless electricity transmission in fullerenes contribute to the search for superconducting materials for practical applications February 9th, 2016

The iron stepping stones to better wearable tech without semiconductors February 8th, 2016

Nano-coating makes coaxial cables lighter: Rice University scientists replace metal with carbon nanotubes for aerospace use January 28th, 2016

Scientists provide new guideline for synthesis of fullerene electron acceptors January 28th, 2016

Nanomedicine

Breaking cell barriers with retractable protein nanoneedles: Adapting a bacterial structure, Wyss Institute researchers develop protein actuators that can mechanically puncture cells February 12th, 2016

Replacement of Toxic Antibacterial Agents Possible by Biocompatible Polymeric Nanocomposites February 12th, 2016

Properties of Polymeric Nanofibers Optimized to Treat Damaged Body Tissues February 12th, 2016

SLAC X-ray laser turns crystal imperfections into better images of important biomolecules: New method could remove major obstacles to studying structures of complex biological machines February 11th, 2016

Announcements

Graphene leans on glass to advance electronics: Scientists' use of common glass to optimize graphene's electronic properties could improve technologies from flat screens to solar cells February 12th, 2016

Breaking cell barriers with retractable protein nanoneedles: Adapting a bacterial structure, Wyss Institute researchers develop protein actuators that can mechanically puncture cells February 12th, 2016

Replacement of Toxic Antibacterial Agents Possible by Biocompatible Polymeric Nanocomposites February 12th, 2016

Properties of Polymeric Nanofibers Optimized to Treat Damaged Body Tissues February 12th, 2016

Patents/IP/Tech Transfer/Licensing

New thin film transistor may lead to flexible devices: Researchers engineer an electronics first, opening door to flexible electronics February 10th, 2016

Joint Efforts by Iranian, Malaysian Scientists Produce Antibacterial Coatings for Isolated Areas February 4th, 2016

Silicon-based metamaterials could bring photonic circuits February 1st, 2016

Therapeutic Solutions International Licenses Dexosome Clinical Stage Cancer Immunotherapy Product From Gustave Roussy European Cancer Centre: FDA Cleared Immuno-Oncology Technology to Resume Clinical Development for Solid Tumor Patients January 27th, 2016

Acquisitions/Mergers/Splits

GLOBALFOUNDRIES Completes Acquisition of IBM Microelectronics Business: Transaction adds differentiating technologies, world-class technologists, and intellectual property July 1st, 2015

Entest BioMedical, Inc. in Discussions to Acquire Nanotechnology Delivery System for Cancer Therapy June 3rd, 2015

Evident Thermoelectrics Acquires GMZ Energy: Investment Accelerates Launch Of Evident's Thermoelectric Modules For Waste Heat May 20th, 2015

Keysight Technologies Begins Trading as Independent Company November 3rd, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic